Our Publications

Ibhazehiebo, K, et al. Metabolism-based drug discovery in zebrafish: An emerging strategy to uncover new anti-seizure therapies: 2020 May

Gurney, ME, et al. Design and synthesis of selective phosphodiesterase 4D (PDE4D) allosteric inhibitors for the treatment of Fragile X Syndrome and other brain disorders. J Med Chem. 2019 May

Ibhazehiebo, K.: A novel metabolism-based phenotypic drug discovery platform in zebrafish uncovers HDACs 1 and 3 as a potential combined anti-seizure drug target. Brain 2018 Mar

Dogra, D.: Kcna1a mutant zebrafish model episodic ataxia type 1 (EA1) with epilepsy and show response to first-line therapy carbamazepine. Epilepsia 2018 Mar

Hagen, TJ. : Discovery of triazines as selective PDE4B versus PDE4D inhibitors. Biorg & Med Chem. 2014 Aug

Dalby, A, et al. A concise synthesis of biaryl PDE4D allosteric modulators. Tetrahedron Lett. 2013

Burgin, AB, et al. Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat Biotechnol. 2010 Jan

Kinch, CD, et al. Selective allosteric inhibition of phosphodiesterase 4B (PDE4B) as a potential anti-seizure treatment for Dravet Syndrome. American Epilepsy Society 2024 Dec